Degradation of poly(d,l-lactic acid) nanoparticles coated with albumin in model digestive fluids (USP XXII)

doi:10.1016/0142-9612(96)86742-1

Biomaterials

Volume 17, Issue 7, 1996, Pages 715-723

https://doi.org/10.1016/0142-9612(96)86742-1 Get rights and content

Abstract

Entirely biodegradable poly(d,l-lactic acid) (PLA₅₀) nanoparticles coated with albumin were prepared by the solvent evaporation technique. Their degradative properties were investigated in simulated gastric and intestinal fluids (USP XXII). The degradation of the albumin coating was monitored by HPLC, whereas PLA₅₀ degradation was determined by size exclusion chromatography (SEC) as well as by the detection of lactate in bulk solution by enzymatic assay. As expected, the coating effect of albumin, a readily digestible protein, rapidly disappeared in both gastric and intestinal media, thus exposing albumin-free PLA₅₀ cores to hydrolytic processes. In pepsin-rich simulated gastric fluid, no degradation of the PLA₅₀ core was observed over 8 h incubation time. In contrast, in pancreatin-rich simulated intestinal fluid, the PLA₅₀ nanoparticles were rapidly converted into lactate. The results showed that the PLA₅₀ degradation was mainly due to an enzymatic cleavage process. Further experiments showed the involvement of lipases in the degradation of the PLA₅₀ core in simulated intestinal fluid.

References (34)

J Kreuter
Peroral administration of nanoparticles
Adv Drug Del Rew
(1991)
P Maincent et al.
Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles
J Pharm Sci
(1986)
G Volkheimer
Persorption of particles: physiology and pharmacology
Pharmacol Chemother
(1977)
P.U. Jani et al.
Nanospheres and microspheres uptake via Peyer's patches: observation on the rate of uptake in the rat after single oral dose
Int J Pharm
(1992)
J.H. Eldridge et al.
Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Payer's patches
J Contr Rel
(1990)
C.G. Pitt et al.
The enzymatic surface erosion of aliphatic polyesters
J Contr Rel
(1984)
S.J. Holland et al.
Polymers for biodegradable medical devices. 1. The potential of polyesters as controlled macromolecular release systems
J Contr Rel
(1986)
S.H. Lee et al.
Adsorption of proteins onto polymeric surfaces of different hydrophilicities
J Colloid Interface Sci
(1988)
V Andrieu et al.
Pharmacokinetic evaluation of indomethacin nanocapsules
Drug Design Delivery
(1989)
C Damgé et al.
New approach for oral administration of insulin with poly-alkylcylanoacrylate nanocapsules as drug carriers
Diabetes
(1988)

M Apprahamian et al.

Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine

Biol Cell

(1987)

P Jani et al.

Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency

J Pharm Pharmacol

(1990)

M.E. LeFevre et al.

Intestinal barrier to large particulates in mice

J Toxicol Environ Health

(1980)

A Schindler et al.

Biodegradable polymers for sustained drug delivery

Contemp Top Polym Sci

(1987)

C.C. Chu et al.

An in vitro evaluation on the stability of mechanical properties of surgical suture materials in various pH conditions

Ann Surg

(1983)

K Makino et al.

Mechanism of hydrolytic degradation of poly(l-lactide) microcapsules: effect of pH, ionic strength and buffer concentration

J Microenc

(1986)

S.H. Hyon et al.

Melt spining of poly-llactide and hydrolysis of the fiber in vitro

Cited by (64)

(In)stability of ligands at the surface of inorganic nanoparticles: A forgotten question in nanomedicine?
2022, Nano Today
Multiple inorganic nanoparticles (NPs) are currently being developed for nanomedicine. Various core materials and shapes are explored, but they all display a common hybrid structure, with organic ligands on their surface. These ligands play a key role in the NP colloidal stability and surface properties, and therefore strongly impact the biological fate of the NPs. However, ligands may be subject to reorganization, degradation, desorption, and exchange, both during their shelf-life and upon exposure to a biological environment. The question of ligand (in)stability at the surface of inorganic NPs has been little addressed in the literature. The goal of this review is to provide a portrait of this critical phenomenon. We identify and review here the different mechanisms likely to promote ligand instability and discuss the resulting biological fate of ligands. This review is aimed to provide a better understanding of these phenomena and to help researchers to design NP-based medicines with better clinical efficacy and translation ability.
Polymer nanoparticles (nanomedicine) for therapeutic applications
2022, Polymeric Biomaterials for Healthcare Applications
Polymeric nanoparticles (PNPs) are tiny solid and colloidal particles with sizes ranging from a few nanometers to 1000 nm, with versatile structures and morphologies. It is an innovative form of materials derived through nanotechnology for technological improvement in drug delivery and other biomedical applications. PNPs are manufactured through the use of both natural and synthetic polymers using different techniques for desired properties. Research has shown the different stimulus responses of these manufactured PNPs. This article reviews the different possible types of PNPs, up-to-date improvements in the synthesis of different PNPs, and the different biomedical applications of PNPs. There are more discoveries to be unleashed year after year, especially with regard to the most recent medical issues such as viral diseases and other illnesses.
In vitro relevant information for the assessment of nanoparticles for oral drug administration
2020, Nanotechnology for Oral Drug Delivery: From Concept to Applications
The choice of a drug route of administration should take into account patient compliance and the achievement of suitable bioavailability. The oral administration route is the one preferred by patients; however, there are many drugs incapable of overcoming the important biological barriers associated. Nanotechnology is now presented as an approach to protect sensitive drugs from the harsh gastrointestinal environment and improve their permeability through the intestinal mucosa. The high versatility of nanoparticles, in terms of size, surface characteristics, composition or drug release profiles, is essential for adapting them to meet their needs. Accordingly, the establishment of appropriate in vitro assays for the evaluation of the quality attributes of the nanoparticles is indispensable for their pre-clinical and clinical development. This chapter reviews the current methods for the in vitro testing of particles, describing their fundaments and highlighting their strengths and weaknesses through their application to different nanotechnology-based formulations. As the interaction of the nanoparticles with the biological media will determine their performance, special attention will be given to the phenomena occurring at the biological-material interface.
Effect of surfactant on the size and stability of PLGA nanoparticles encapsulating a protein kinase C inhibitor
2019, International Journal of Pharmaceutics
Nowadays many drugs with improved therapeutic efficacy are discovered but cannot be utilized due to their low solubility and insufficient bioavailability. An example of such a drug molecule is a protein kinase C inhibitor that influences an enzyme which plays an important role in several signal transduction cascades. The aim of this study was to formulate a stable nanoparticle dispersion of the PKC inhibitor encapsulated into PLGA nanoparticles (NPs). Encapsulation of the PKC inhibitor into PLGA NPs of 100–200 nm diameter should provide a targeted delivery to the inflammation sites. The NPs were prepared via nanoprecipitation and different surfactants were investigated: Fully and partially hydrolyzed poly(vinyl alcohol) (PVA, Mowiol X-88 and X-98), poloxamers (Pluronic F68 and F127) and polysorbates (Tween 20 and 80). From all surfactants tested, only NPs prepared with partially hydrolyzed PVA (Mowiol X-88) provided the desired stability throughout the downstream processes. These NPs were subsequently analyzed regarding their particle size, polydispersity, encapsulation efficiency and loading capacity. Dynamic light scattering results revealed that monodisperse NPs of 150–220 nm were formed, a size range that favors targeted delivery. The drug encapsulation efficiency varied from 31 to 75% with a drug loading of 1.3–2%. Moreover, the long-term stability was studied and the residual amount of PVA of the NP solutions was quantified via nuclear magnetic resonance (NMR) measurements. The shell-less hen’s egg model was used to test toxic effects (hemorrhage, vascular lysis, thrombosis, hemolysis and lethality) of the NPs in a more complex biological system under dynamic flow conditions.
Influence of the surface properties of nanocapsules on their interaction with intestinal barriers
2018, European Journal of Pharmaceutics and Biopharmaceutics
Citation Excerpt :
As expected, due to the important exposure to the enzymes of the oily core of the NE prepared without non-ionic surfactants, this was the formulation that presented the highest degradation by pancreatic enzymes (70% in 20 min), being its area under the curve significantly higher than those corresponding to CS NCs (p ≤ 0.0001) and PARG NCs (p ≤ 0.001). This was mainly attributed to the interaction of the pancreatic lipase with the oily droplets [19,60,68], being this degradation slightly reduced by the CS and PARG coatings. We have speculated that this limited protective effect of the polymeric shell could be attributed to the presence of amylases, enzymes with the capacity of degrading CS through the α(1,4) glycosidic bond cleavage [69–71], and peptidases, enzymes capable of degrading PARG backbone through the peptide bond [68,72].
Despite the convenience of the oral route for drug administration, the existence of different physiological barriers associated with the intestinal tract greatly lowers the bioavailability of many active compounds. We have previously suggested the potential polymeric nanocapsules, consisting of an oily core surrounded by a polymer shell, as oral drug delivery carriers. Here we present a systematic study of the influence of the surface properties of these nanocapsules on their interaction with the intestinal barriers. Two different surfactants, Pluronic®F68 (PF68) and F127 (PF127), and two polymeric shells, chitosan (CS) and polyarginine (PARG) were chosen for the formulation of the nanocapsules. We analyzed nine different combinations of these polymers and surfactants, and studied the effect of each specific combination on their colloidal stability, enzymatic degradation, and mucoadhesion/mucodiffusion. Our results indicate that both, the polymer shell and the surfactants located at the oil/water interface, influence the interaction of the nanocapsules with the intestinal barriers. More interestingly, according to our observations, the shell components of the nanosystems may have either synergic or disruptive effects on their capacity to overcome the intestinal barriers.
Fab-conjugated PLGA nanoparticles effectively target cancer cells expressing human CD44v6
2018, Acta Biomaterialia
Targeting of CD44 isoforms containing exon v6 (CD44v6) represents a viable strategy for the therapy and/or early diagnosis of metastatic cancers of the epithelium (e.g. gastric and colorectal cancer). We developed and characterized poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles (NPs) modified with polyethylene glycol (PEG) and engrafted, by site-directed conjugation, with an engineered human Fab that specifically target human CD44v6 (v6 Fab-PLGA NPs). The v6 Fab-PLGA NPs displayed spherical morphology around 300 nm and were negatively charged. They strongly bound to a CD44v6-derived peptide and, more importantly, to cells that endogenously and exogenously express CD44v6, but not to non-expressing cells and cells expressing the standard isoform of CD44. The v6 Fab-PLGA NPs also recognized CD44v6 in tumor sections from cells grown subcutaneously within mice. The NPs had nominal cytotoxicity at 50 µg/mL and withstood simulated intestinal fluid exposure. Interestingly, v6 Fab-PLGA NPs cryopreserved in 10% trehalose and stored maintained specific cell binding. In conclusion, we envision NPs targeting CD44v6 as potential in vivo diagnostic agents and/or as anti-cancer agents in patients previously stratified with CD44v6⁺ carcinomas.
The v6 Fab-PLGA NPs displayed many favorable qualities as a potential CD44v6-targeted drug and/or diagnostic delivery agent. The NPs were designed for optimal ligand orientation and for immediate administration into humans.
v6 Fab-PLGA NPs strongly bound to cells that endogenously and exogenously express CD44v6, but not to non-expressing cells and cells expressing the standard isoform of CD44. Binding ability was retained after freeze-drying and long-term storage, providing evidences on the stability of Fab-functionalized NPs.
These NPs can potentially be used as an in vivo diagnostic from parenteral or oral/rectal administration.

View all citing articles on Scopus

View full text

PaperDegradation of poly(d,l-lactic acid) nanoparticles coated with albumin in model digestive fluids (USP XXII)

Abstract

Adv Drug Del Rew

J Pharm Sci

Pharmacol Chemother

Int J Pharm

J Contr Rel

J Contr Rel

J Contr Rel

J Colloid Interface Sci

Pharmacokinetic evaluation of indomethacin nanocapsules

Drug Design Delivery

New approach for oral administration of insulin with poly-alkylcylanoacrylate nanocapsules as drug carriers

Diabetes

Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine

Biol Cell

Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency

J Pharm Pharmacol

Intestinal barrier to large particulates in mice

J Toxicol Environ Health

Biodegradable polymers for sustained drug delivery

Contemp Top Polym Sci

An in vitro evaluation on the stability of mechanical properties of surgical suture materials in various pH conditions

Ann Surg

Mechanism of hydrolytic degradation of poly(l-lactide) microcapsules: effect of pH, ionic strength and buffer concentration

J Microenc

Melt spining of poly-llactide and hydrolysis of the fiber in vitro

Paper
Degradation of poly(d,l-lactic acid) nanoparticles coated with albumin in model digestive fluids (USP XXII)